On Tuesday, Shares of Pfizer Inc. (NYSE:PFE), gained 3.70% to $32.53.
Pfizer declared that it has accomplished its acquisition of Hospira, Inc.
Pfizer’s GEP business now has a leadership position in the large and growing sterile injectables category, with a robust portfolio of both generic and branded products. The global market for generic sterile injectables is estimated to be $70 billion in 2020. In addition, GEP has significantly advanced its biosimilars business with a broadened portfolio of marketed products and pipeline assets, which will benefit from Pfizer’s best-in-class capabilities in monoclonal antibody development and manufacturing. The global market for biosimilars is estimated to be about $20 billion in 2020. The industry-leading medication administration systems business, which is now part of GEP, is a complementary business that benefits patients and healthcare systems through improved accuracy and productivity in clinical care. Pfizer is now poised to use its commercial capabilities, global scale, scientific expertise, and manufacturing prowess, which now comprises two of the largest sterile injectable manufacturing facilities in the world, to maximize the global potential of its improved GEP portfolio of sterile injectables, biosimilars and medication administration systems.
Pfizer continues to expect the transaction to be right away accretive to adjusted diluted EPS1 upon closing and accretive by $0.10 - $0.12 per share in the first full year after the close, with additional accretion anticipated thereafter. In addition, Pfizer anticipates the transaction will deliver $800 million in annual cost synergies by 2018. Pfizer intends to update its 2015 financial guidance in the coming weeks to incorporate Hospira. The guidance will reflect the anticipated contribution from Hospira operations from the time of the completion of the Hospira merger to Pfizer’s fiscal year end, which is November 30, 2015 for Pfizer’s international fiscal year and December 31, 2015 for Pfizer’s U.S. fiscal year.
Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. The company operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments.
Shares of Hewlett-Packard Company (NYSE:HPQ), inclined 2.22% to $27.59, during its last trading session.
Hewlett-Packard Company unveiled the expansion of its rapidly growing Instant Ink replacement service to its new HP ENVY, OfficeJet and DeskJet printers. The new printers come HP Instant Ink ready and offer a choice of monthly and yearly ink subscription plans starting at only $2.99 a month.
With HP Instant Ink, customers select a plan based on how much they want to print and HP takes care of the rest. You never run out of ink, and printing costs up to 50 percent less.
Eliminating the anxiety of running out of ink at the worst time, the new fall line comes with smart cartridges in the box that can reorder ink before they run out and deliver it directly to the customer’s door.
HP Instant Ink is one of the fastest growing web-based paid services, adding more than one new customer every minute of every day. In fact, a recent survey conducted by Harris Poll found 62 percent of those who intend to purchase a printer in the next year would be interested in an ink delivery service like HP Instant Ink.
“Customers want printing to be affordable, convenient and meaningful,” said Stephen Nigro, senior vice president, Imaging and Printing, HP. “With HP Instant Ink, customers can enjoy low cost of ownership and print what matters most to them without the worry of running out of ink or spending too much.”
Hewlett-Packard Company, together with its auxiliaries, provides products, technologies, software, solutions, and services to individual consumers and small- and medium-sized businesses (SMBs), in addition to the government, health, and education sectors worldwide.
Finally, MannKind Corp. (NASDAQ:MNKD), ended its last trade with 4.76% gain, and closed at $4.07.
MannKind Corporation declared the renewal of its shelf Registration Statement on Form S-3, as filed with the Securities and Exchange Commission, replacing the previous shelf, which expired on August 31, 2015. Conpresently, MannKind also renewed its At-The-Market Issuance Sales Agreements with Meyers Associates, L.P. (now doing business as BP Capital, a division of Meyers Associates, L.P.) and with MLV & Co. LLC providing for sales, from time to time, of the Company’s common stock.
MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes in the United States.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.